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Critical quality attributes1. Introduction
Drug nanocrystals are pure solid drug nanoparticles, which are cov-
ered by a stabilizer layer [1–4]. In rare cases, no stabilizer is needed [5].
But, mostly a layer of polymer(s) and/or surfactant(s) is needed for sta-
bilizing nanoparticles against particle aggregation. Stabilizer layer can
be based on only one material, but often also a mixture for example of
one polymer and one surfactant is used [6]. Functionality of drug
nanocrystals can be reached via adding some functional/linking groups
on the stabilizer layer [7–9]. Often nanocrystals are referred to solid
micelles.
Cocrystals are multicomponent solids, where the crystal contains
two or more molecular components, in pharmaceutics, active pharma-
ceutical agent (API) and cocrystal former, coformer [10–14]. In
cocrystals different components have well-defined stoichiometric
structure in a single homogenous crystal phase. Cocrystals are formed
via different types of molecular interactions: hydrogen bonds, π - π
stacking and van der Waals forces (Fig. 1). In cocrystals, drug and
coformer interact nonionically, which separates them from salts [14].
Hence, cocrystals provide another possibility for poorly soluble drugs
for improved solubility: they often have no ionic functional groups
that are demanded for salt formation. Often cocrystals are referred to
solvates/hydrates, where typically nonvolatile coformer is not a solvent.V. This is an open access article und
ical guidelines for the charac
liv. Rev. (2018), https://doi.oor water. Pharmaceutical cocrystals have been studied for years for im-
proved solubility, and nano-cocrystals are just cocrystals in nanometer
scale [15,16].
Besides solubility, cocrystallization can improve also other physico-
chemical properties of the drug: chemical stability, dissolution rate, me-
chanical properties (process ability) of the drug, hygroscopicity,
compressibility and flowability [17]. For example, drug melting point
can be changed via cocrystal formation [18]. Typically, cocrystalline
drug has a melting point in between of the melting point of the pure
drug and the coformer. The situation can also be different, and in that
case, the high melting point indicates poor solubility. When the
cocrystals are made in nanoscale, i.e. nano-cocrystals, for example solu-
bility and dissolution rate can be improved even further. Improvements
are not only due to the cocrystals structure, but also due to the
nanonized size scale, which means increased surface area for
dissolution.
If drug nanocrystals and nano-cocrystals are compared to other mo-
lecular level techniques utilized for improved solubility, they differ from
salts in that they do not require any ionic interactions. This means that
non-ionic materials can be used. To amorphous systems the difference
is that crystal form is thermodynamically stable, but the stability chal-
lenge is in aggregation tendency of small particles. With both the drug
nanocrystals and drug nano-cocrystals, the solubility enhancement
can in best cases be in the same level as with amorphous systems
[19,20]. Cocrystal solubility enhancement can be tailored to a certain
level by solution pH changes, solubilizing agent concentration orer the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1.Hydrogen bonding groups typically utilized in formation of pharmaceutical cocrystals:
(1) carboxylic acid homosynthon; (2) carboxylic acid – pyridine heterosynthon; (3) amide
homodimer; (4) carboxylic – amide heterosynthon; (5) alcohol - ether heterosynthon.
Reprinted from [10] with permission from Elsevier.
2 L. Peltonen / Advanced Drug Delivery Reviews xxx (2018) xxx–xxxcoformer concentration (Fig. 2) [11, 21–23]. More precise description of
cocrystal formation can be found for example from [11,24,25].
Cocrystal formation is utilized mainly for improved solubility and
hence drug is often hydrophobic, but the coformer hydrophilic in na-
ture. Solubility enhancement is correlated with coformer solubility, be-
cause coformers decrease the solvation barrier of the whole cocrystal
system [11].
Typically drug nanocrystals and nano-cocrystals dissolve almost im-
mediately, when they get into contact with the fluids in vivo. However,
for example for intravenous (i.v.) administration [26] or implants, when
the dissolution and drug release is not necessarily immediate, the size,
shape, surface coating/charge, and morphology are important product
properties. Sigfridsson et al. [26] studied in vivo distribution of drug
nanocrystals in mice after i.v. administration. Nanocrystals were pro-
duced by milling with different surface materials: DSPE-PEG2000 (1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(poly(eth-
ylene glycol)) PEG-ylated and Pluronic F127, bothwith orwithout poly-
vinylpyrrolidone K30 (PVP)/Aerosol. DSPE-PEG2000 PEG-ylated
particles had prolonged circulation time (particle elimination half-life
9 min) compared to DSPE-PEG2000/PVP/Aerosol formulation (half-life
3 min), while both the Pluronic F127 formulations possessed similar
half-lives (9min). In the study, dissolved drug were accumulated in he-
patocytes. But, undissolved particleswere accumulated in the liver sinu-
soidal endothelial cells and Kupffer cells. Further, DSPE-PEG2000/PVP/
Aerosol stabilized particles were accumulated more in the liver, com-
pared to Pluronic F127/PVP/Aerosol stabilized particles.Fig. 2. Solubility of cocrystals. Solubility as a function of (a) pH, (b) concentration of solubilizin
concentrations of drug and coformer. Reprinted from [11] with permission from Elsevier.
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tant to recognize, if the particles are meant to be dissolved immediately
or if the aim is controlled drug release from solid particles: this affects
the critical quality attributes, CQAs, and desired particle properties of
the end product [27–29]. In this review, most important physicochem-
ical properties, based on CQAs, of drug nanocrystals and nano-
cocrystals are presented with practical case studies. Physical stability
(stable particle size and solid state form), solubility behavior, and drug
release testing are discussed in detail. Suitable analytical techniques,
their pros and cons, are described from the practical point of view.
Main emphasis is put on the characterization of fast dissolving systems,
but controlled release systems are also shortly discussed.
2. Critical quality attributes of drug nanocrystals and nano-
cocrystals
Depending on the target product profile, quality attributes of the
drug nanocrystals and nano-cocrystals may differ. Shortly, depending
on the in vivo faith of the nanoparticles, they can be divided into two
classes: (1) nanoparticlesmeant to be taken up by the cells as solid par-
ticles, and (2) fast dissolving nanoparticles where fast dissolution is
followed by absorption of dissolved drug.
2.1. Solid nanoparticles in vivo
As already discussed, nanoparticles can have different in vivo phar-
macokinetic profiles, biodistributions and therapeutic efficacy due to
the size, shape, surface charge and surface hydrophobicity properties
[29]. These properties are very important, if the nanosystems are not
intended to be dissolved immediately. If the particles are taken up by
the cells as solid particles (before particle dissolution, Fig. 3) particle
shape has been shown to affect cellular uptake kinetics and mecha-
nisms, level of uptake, and intracellular distribution, and, hence, cyto-
toxicity [30]. Anticancer agents reached improved therapeutic efficacy,
when non-spherical particles were used [30]. Nanoparticle shape
(spherical vs. rod shaped) caused differentmembrane bending energies
during endocytosis, which affected cell uptake [31]. Xie et al. [32] stud-
ied the shape effect on cellular internalization of gold nanoparticles
with RAW264.7 cells. Studied shapes were stars, rods and triangles. In
the study, the cellular uptake was highest with triangle shaped nano-
particles, and lowest with star shaped systems.
Particles are mostly internalized into the cells via pinocytosis
(micropinocytosis or macropinocytosis) or phagocytosis [34,35].
When detecting only the particle size, Swanson and Watts [36] found
out in their study that particle sizes above 200 nm were internalized
by phagocytosis or micropinocytosis, while particles below 200 nm
were taken up in all the cell types via micropinocytosis (either clathrin
mediated, caveolae or lipid raft mediated or clathrin or caveolae inde-
pendentmechanisms) [37]. However, besides particle size, other factors
like particle shape and surface properties, aswell as studied cell line, are
affecting uptake mechanisms. In the following section, case studiesg agent, and (c) concentration of coformer. Dashed line corresponds stoichiometric (1:1)
terization and quality control of pure drug nanoparticles and nano-
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Fig. 3. Cell uptake of paliperidone palmitate drug nano−/microcrystals in RAW264.7macrophages by CARS (Coherent Anti-Stokes Raman Scattering) imaging. Figure (a) and (e): low and
highmagnification bright field images; figures (b) and (f): F-CARS (forward-detected CARS; red)/TPEF (two-photon excitation fluorescence; green) mergedmicrographs; figures (c) and
(g): orthogonal projections of z-stacked F-CARS/TPEF overlays showing intracellular solid nano−/microcrystals; and figures (d) and (h): 3-D reconstructions of the z-stacked F-CARS/TPEF
overlays. The arrows show nano−/microcrystals adsorbed onto the cell surface (white arrow) and phagocytosed (black arrows). Incubation timewith nano−/microcrystals 2 h (a–d) and
24 h (e–h). Reprinted from [33] with permission from Elsevier. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
3L. Peltonen / Advanced Drug Delivery Reviews xxx (2018) xxx–xxxrelated to cell uptake of nanoparticles with different size, surface prop-
erties and shape, are presented, but the reader should be aware of that
cell uptake is complex process with many variables and more system-
atic studies are needed in that area.
When cell uptake of gold nanoparticles with particle size of 80-
90 nm were studied, the uptake was following: triangle shaped nano-
particles were taken up via clathrin mediated mechanisms and rod
shaped via caveolae and clathrin mediated mechanisms [32]. Clathrin
mediated endocytosis could be followed by exocytosis where part of
the nanoparticleswere returned to extracellular area [38]. Caveolaeme-
diated cell uptake can be either via caveosome pathway, where part of
the nanomaterial is removed from the endoplasmic reticulum/Golgi
body, or via endosomal route, where nanomaterial may be exocytosed.
Accordingly, in the caveolaemediated route therewere different exocy-
tosis pathways, which was suggested to be the reason behind the lower
level of cell uptake with rod shaped nanoparticles.
Uptake studies of negatively charged 10-hydroxycamptothecin (ap-
proximated particle size 130 nm) with 4T1 cancer cell line showed that
internalizationwasmainlymediated by clathrin dependent endocytosis
[5]. Nanoparticle shape were also shown to enhance drug therapy in
lung and brain endothelium [39] and in vascular targeting [40]
combined with lower level of liver and spleen accumulation [41]. Be-
sides the shape, surface layer properties affect the internalization:
Poloxamers are well known to interact with the cell membrane, and
Poloxamer 407 stabilized nanosystems were efficiently internalized by
cancer cells in vitro [42,43].
When considering effect of surface charge on cell interactions,
phagocytic cells uptake more readily negatively charged particles than
neutral ones, and negatively charged particles are cleared faster from
the blood [44]. On the other hand, positively charged nanosystems can
interact with negatively charged serum proteins [45] and alsowith neg-
atively charged eukaryotic cell membranes [46]. Cancer cell membranes
can overexpress negatively charged phospholipids [47]. The cell uptake
of 10-hydroxycamphothecin nanocrystals (zeta potential−27mV) into
4 T1 cancer cellswasmainlymediated by clathrin-dependent endocyto-
sis [5].Please cite this article as: L. Peltonen, Practical guidelines for the charac
cocrystals in the pharmaceut..., Adv. Drug Deliv. Rev. (2018), https://doi.oDrug nanocrystals/nano-cocrystals can be utilized for controlled
drug delivery [8,48–52]. For example, in oral delivery, drug nanocrystals
were imbedded into matrix structures for sustained drug release [8],
and in vivo passive accumulation of drug nanocrystals was reached via
mononuclear phagocytic system (MPS) cells, which led to passive accu-
mulation of particles inMPS-rich organs, like liver, spleen and lung [49].
Effect of particle size on drug release profile was shownwith two differ-
ently sized oridonin nanosuspensions: formulation A with approxi-
mated particle size of 100 nm and formulation B 900 nm [51]. With
100 nm nanocrystals, in vitro dissolution was completed in 10 min,
while with 900 nm nanocrystals only 85.2% of drug was dissolved
after 2 h time. Tissue distribution after intravenous administration
showed that pharmacokinetic profile and biodistribution of drug from
100 nm oridonin nanosuspension was similar to solution. However,
900 nm nanosuspension showed higher drug uptake in the reticuloen-
dothelial system (RES) organs and had markedly different pharmacoki-
netic profile compared to 100 nm particles. An example of long-acting
intramuscularly injected drug nano−/microcrystal system is Xeplion®
with paliperidone palmitate as an active agent, which has therapeutic
drug release profile up to several months [52,53].2.2. Fast dissolving nanosystems
Above mentioned examples do emphasize the importance of exact
knowledge of particle size, size deviation, shape, composition and mor-
phological information, which affect on cell uptake.With fast dissolving
nanosystems, the aim is that particle dissolution in vivo is immediate,
which is followed by efficient drug permeation (of dissolved drug);
most of the drugs are belonging to Biopharmaceutics Classification Sys-
tem (BCS) class II, where the poor solubility is the rate limiting step for
permeation [7,54,55]. In these systems, particle shape or size does not
affect cell uptake (drug permeates in dissolved form), but do affect for
example dissolution rate, solubility, and formulation related factors
like aggregation tendency and physical stability of the system. Accord-
ingly, particle size should be tailored to be optimum according to theterization and quality control of pure drug nanoparticles and nano-
rg/10.1016/j.addr.2018.06.009
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in the Quality Target Product Profile (QTPP).
2.3. Critical quality attributes, CQAs, for drug nanosystems
Critical Quality Attributes, CQAs are selected based on QTPP. For ex-
ample particle size, shape, solid state properties or cocrystal structure,
stability or solubility can be CQAs [30,56]. Stability, and especially phys-
ical stability, is important CQA. In the case of drug nanocrystals and
nano-cocrystals, physical stability can be divided to i) constant particle
size and particle size deviation and ii) unaltered/controlled solid state.
In the case of drug nano-cocrystals solid state characterization is re-
quired also to confirm the formation of certain cocrystal structure:
that nonionically interacting drug(s) and coformer(s) co-exist in the
unit cell [14].
Other aspects of stability issues of cocrystals are stability against hu-
midity, thermal stability, chemical stability and solution stability (ability
to stay in solution). With cocrystals higher amount of water can state
stability problems [18]. Solution stability is important issue in further
drug development with both the drug nanocrystals and nano-
cocrystals, because the apparent solubility of both the systems are
higher than thermodynamic solubility of the drug, i.e. the solution is in
supersaturated state. Accordingly, uncontrolled crystallization/precipi-
tation may follow after the fast dissolution, and this can hinder perme-
ation [50]. Drug release tests for nano-cocrystals are required in order to
show that drug is dissociated from the co-crystal structure and dissolves
as an original drug.
3. Characterization and quality control of drug nanocrystals and
nano-cocrystals
The quality and analysis of nanosystems is much more complicated
as compared to bulk material or even to microparticle systems [27]. In
nanoscale many physical properties are different from corresponding
bulk values, for example, in submicron area, apparent solubility can be
considerably higher than corresponding saturated solubility value of
bulk material [28]. Nanoparticles are inherently unstable and have
high tendency for aggregation. Also, the role of sampling is crucial for
nanoparticulate systems, as well as sample handling. Care must be
taken that sampling is representative for the whole batch. In particle
sizing, for example, for very polydisperse samples incorrect particle
size information may be resulted after the sedimentation of larger par-
ticles, when only the smaller particles are analyzed, or, other way
around, the smallest particles are dissolved during the sample dilution.
Most relevant characterization techniques for nanosystems are listed in
Table 1.
3.1. Particle size, shape and morphology
Particle size, size deviation, shape andmorphology are important in-
dicators for small particle systems. The size, size deviation as well as
shape and morphology are related to stability, physicochemical perfor-
mance like dissolution and solubility as well as cell uptake and final fate
in vivo of nanosizedmaterials, as already described earlier [57,58]. Drug
nanocrystals can be stabilized against aggregation with the aid of stabi-
lizer layer [59]. In general, when thinking about the effect of particle size
and size deviation on stabilization, the smaller the particle size, the
more the particles tend to aggregate. Similarly, more heterogeneous
particles in size (larger size deviation) are also more unstable.
When selecting the measurement technique, it is important to take
into account the measurement purpose (e.g. research purposes vs. pro-
cess/quality control, measurement time). In general, sizing techniques
can be classified into imaging and non-imaging techniques. In imaging
techniques some kind of visualization of the particles are reached, and,
besides size and size deviation, additional information like shape, mor-
phology, degree of aggregation, that are not available fromnon-imagingPlease cite this article as: L. Peltonen, Practical guidelines for the charac
cocrystals in the pharmaceut..., Adv. Drug Deliv. Rev. (2018), https://doi.otechniques, are also available [56]. Most utilized techniques are light
scattering [6] and electronmicroscope based techniques [57]. Especially
for research purposes, and for new samples, combination of two or
more techniques, for example light scattering and electron microscopy,
are preferred.
3.1.1. Non-imaging techniques
Light scattering techniques are fast, precise, sensitive, and utilizable
for a wide particle size area from smallest nanoparticles to micron sized
particles. They can be divided into twomethods: the Static Light Scatter-
ing (SLS) and theDynamic Light Scattering (DLS) [60]. In SLS,material is
illuminatedwith a light beam and the averaged scattered light intensity
is measured over a given time interval at various scattering angles, and
based on a scattering theory (model) the information is derived to par-
ticle size information. In DLS the fluctuations in the intensity of the light
scattered by the particles is measured as a function of time at a fixed
angle in order to calculate the particles diffusion coefficient, which in
turn can be used to determine their hydrodynamic radius. DLS method
is more suitable for submicron particles. The hydrodynamic radius can
be affected by the liquid environment during the measurement, espe-
cially with small charged particles (b 300 nm), where the electric dou-
ble layer leads larger particle size results [60]. For example, when
mean particle sizes of gold nanoparticles weremeasured, themean par-
ticle size by transmission electronmicroscope, TEM, was approximately
50 nm,while the hydrodynamic size inDLSwas 60–70 nm [33]. For TEM
analysis samples were dried at room temperature, while DLS measure-
ments were done in aqueous solution, and the hydration layer around
the nanoparticles in aqueous environment made DLS results larger
than TEM values.
Measurements of samples with large particle size deviation, i.e. het-
erogeneous/polydisperse samples, is challenging by light scattering
techniques, and in these cases larger particles are overstressed in theterization and quality control of pure drug nanoparticles and nano-
rg/10.1016/j.addr.2018.06.009
5L. Peltonen / Advanced Drug Delivery Reviews xxx (2018) xxx–xxxresults. In some cases prehandling is possible, but, if sample prehandling
is used, care must be taken in order to properly interpret the results. Es-
pecially, if quantified results are needed. Care should be taken that no
artefacts are measured: for example in the presence of surfactants
(used as stabilizers for drug nanocrystals) micelle formation is possible,
which are also measured by DLS.
In light scattering techniques, scattering intensity is dependent on
the scattering angle, absorption, particle size, and refractive indices
(particle material and dispersion medium) [60]. Uncertainty in any of
these parameters can cause alterations in the results. For example,
small difference between the refractive indicesmay cause unreliable re-
sults. Also, dynamic processes like Brownianmotion or particle aggrega-
tion can affect the results. Normally, before the measurements, sample
needs to be diluted, and this dilution step may induce some changes
in particle size deviation. When extremely fast dissolving drug
nanocrystals are diluted, dissolution may take place before measure-
ment and the particle size value is changed towards larger values. In di-
lution step, saturated drug solution is recommended to be used in order
to minimize particle dissolution during dilution step (Fig. 4) [48,62].
Sampling and sample handling are in utmost importance in all the par-
ticle size determinations: themore heterogeneous the sample, themore
important is reliable sampling. Most of the problems in particle size
measurements are due to incorrect sampling and/or sample preparation
before themeasurement, and extreme caremust be followed in order to
reach representative samples [63].
In light scattering techniques the particle size information is re-
vealed from the scattering data with the aid of special algorithms,
where mostly spherical particle shape approximation is used as a
bases [27,62]. When drug nanocrystals are made by top-down tech-
niques, result can be for example needle shaped particles with very dif-
ferent particle dimensions depending on the detection direction.
Accordingly, non-spherical particles may lead misleading particle size
information: the less the particle size remains spherical, the greater
the difference between the measured particle size and actual particle
size. This needs to be taken into account, especially, if particle size mea-
surements of differently shaped particles are compared. More precisely,
particle shapes, where one dimension differs a lot from the others, like
needles, discs or flakes, can be problematic. Particle size analyses are rel-
ative measurements. Comparison of values measured by different tech-
niques or even same technique in different laboratories and conditions
should be carefully considered.
In DLS, size distribution can be an intensity or volume based distri-
bution [6]. In intensity based measurements, light scattered by eachFig. 4. Particle size measurements for rutin nanosuspensions measured by dynamic light scatte
dispersion media. Reprinted from [62] with permission from Elsevier.
Please cite this article as: L. Peltonen, Practical guidelines for the charac
cocrystals in the pharmaceut..., Adv. Drug Deliv. Rev. (2018), https://doi.oparticle is related to the particle size. In volume based measurements
contribution of particles is related to their volume. Volume based mea-
surements overstress the fraction of larger particles, and intensity based
measurements are recommended for nanoparticulate systems. But, the
overstress of larger particles in the volume based measurements can be
utilized in comparison of different nanosuspensions, due to its higher
sensitivity to the larger particles [6]. In nanoparticle size range, light in-
tensity is proportional to the sixth power of particle diameter, and thus
the existence of a small number of larger particles can dominate the par-
ticle size results.3.1.2. Imaging techniques
Electron microscopy techniques, like scanning electron microscopy,
SEM, and transmission electron microscopy, TEM, can be utilized for
particle sizing, and they give at the same time also particle shape and
morphology information [15,64]. SEM requires high vacuum, and
clean, dry and electrically conductive samples. This often means that
samples needs to be for example platinum or gold coated before the
measurement, which can alter the surface characteristics. If sample
needs to be dried before analysis, drying method can alter the sample
properties, too (Fig. 5). More advanced technique is environmental
scanning electron microscopy, ESEM, which does not require high vac-
uum, and wet or oily samples can be analyzed. However, in most
cases with drug nanocrystals and nano-cocrystals, SEM/TEM are recom-
mended techniques for particle shape analysis.
Atomic force microscopy, AFM, can also be utilized for size, shape
andmorphological studies, though it has not been used as often as elec-
tron microscopy, EM, techniques [65]. For purely size determinations
statistically relevant number of particles should be measured, and
AFM as well as EM techniques are very laborious and time consuming.
Techniques are also analyzing only part of the sample. In small particle
studies, AFM is more demanding and, hence, less utilized in these pur-
poses. In AFM, a cantilever with a very sharp tip scans the sample sur-
face. When the tip approaches the analyzed surface, the close-range
attractive force between the surface and the tip get the cantilever to de-
flect towards the surface.When the cantilever is further closing the sur-
face (the tip in contact with the surface), increasing repulsive force is
acting and the cantilever is deflected away from the surface.Movements
of the cantilever are detected by changes in the direction of reflected
laser beam, which can be recorded by a position-sensitive photo
diode. Topographic map of the sample surface can be formed based on
the movements of the cantilever over the scanned surface.ring technique in unsaturated (left), partly saturated (middle) and fully saturated (right)
terization and quality control of pure drug nanoparticles and nano-
rg/10.1016/j.addr.2018.06.009
Fig. 5. Scanning electron microscopy figures of loviride nanocrystals with different sample preparations. (a) and (b) drying in air; (c) and (d) freeze-drying; and (e) and (f) dispersion of
freeze-dried sample. Reprinted by permission from Springer Nature from [61].
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suming for exact particle size analysis. Light scattering based techniques
are fast and they should be the first choice for particle sizing. The value
of imaging techniques is that they give also the particle shape informa-
tion, and traditional SEM/TEM are recommended for that analysis. For
quality control purposes light scattering measurements alone are
enough, but for research purposes and especially with unknown sam-
ples combination of imaging technique, like SEM, with light scattering
technique, like DLS, is recommended.
3.2. Solid state properties and chemical stability
Solid state form of thematerial (crystal form, degree or crystallinity,
hydrates, solvates, amorphous form) affects physical performance of the
system like solubility and dissolution rate. Thermodynamically most
stable form has the lowest solubility. Accordingly, exact knowledge of
material properties is required [66,67]. Always, when energy input,
like temperature changes or mechanical energy, is involved, polymor-
phic changes or formation of amorphous material is possible, but also
chemical degradation may take place.
Solid state analysis and interaction studies can be performed by
thermal analysis, mostly differential scanning calorimetry, DSC, or dif-
ferent spectroscopic techniques, like X-ray diffraction, XRD, infrared,
IR, and Raman spectroscopy, and less utilized solid state nuclear mag-
netic spectroscopy, SSNMR. Most standard way to detect chemicalPlease cite this article as: L. Peltonen, Practical guidelines for the charac
cocrystals in the pharmaceut..., Adv. Drug Deliv. Rev. (2018), https://doi.opurity of the sample is high performance liquid chromatography,
HPLC, but liquid chromatography - mass spectrometry, LC-MS, tech-
niques can also be utilized.
When drug nanocrystals are produced via top-down techniques,
most common techniques being high pressure homogenization and
wet milling, the process is typically performed in aqueous dispersion.
In these cases, water stabilizes the crystallinity of the drug by acting as
a plasticizer [68]. In bottom-up techniques, formation of amorphous
material is more typical, especially in liquid atomization based tech-
niques [69]. It is important to be aware of, that, if thermodynamically
less stable form is present, changes in solid state form during storage
or even during administration are possible, which can alter the biophar-
maceutical properties of the system [54,70,71]. In drug nanocrystal
studies, DSC and XRD are mostly used techniques for solid state charac-
terization, but also techniques like Raman have been used. Utilization of
IR in drug nanocrystal studies is related to recognition of interactions
between the drug and excipient(s) in the system.
For cocrystals, it is important to confirm with suitable analytical
techniques that drug and coformer coexist in the cocrystals
interacting nonionically, and that drug and coformer are present in
the unit cell [14]. Regulatory classification of pharmaceutical
cocrystals by United States Food and Drug Administration, US FDA,
is similar to drug polymorphs and above mentioned proofs are re-
quired for new drug applications, NDAs, and abbreviated new drug
applications, ANDAs. Pharmaceutical cocrystal analyses are mostlyterization and quality control of pure drug nanoparticles and nano-
rg/10.1016/j.addr.2018.06.009
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SSNMR, but less frequently.
3.2.1. Thermal analysis
Thermal analysis detects the material properties as a function of
temperature. As stated above, most used are different applications of
DSC, where by measuring the heat flow, endothermic and exothermic
events, like melting point or glass transition temperature, recrystalliza-
tion, can be recognized. Modulated temperature DSC, MT-DSC, is more
sensitive and has higher separation capacity with overlapping thermal
events, because it analyses both quasistatic material properties as well
as frequency dependency of thermal events. Thermogravimetric anal-
ysis, TGA, measures sample mass during the heating, and it is very
convenient for example in detecting the exact structure of solvents
or hydrates. Case studies demonstrating utilization of thermal ana-
lytical techniques in nanosystems characterization are presented in
Section 3.2.3.
3.2.2. Spectroscopic techniques
Most common spectroscopic methods in pharmaceutical analysis
are different kind of X-ray (XRD and x-ray powder diffraction, XRPD),
infrared and Raman techniques. In X-ray techniques, a beam of incident
X-rays are diffracted to certain directions, and from the diffractrogram
the atomic and molecular level structure of the material can be calcu-
lated. IR and Raman are vibrational spectroscopic techniques, where IR
operates in IR region and Raman in visible, near IR or near-ultraviolet
(UV) wavelengths. For example, interactions between ketoprofen and
different polymers (Eudragit RS and Eudragit E) were confirmed by IR
analysis; acidic ketoprofen interacted with the ester groups in polymer
[72]. Molecules can absorb certain frequencies, which are characteristic
to the transition energy of the vibrating bond or functional group in the
molecule. Ramanmeasures inelastic scattering, Raman scattering, and it
is able to detect vibrational, rotational and other low-frequency transi-
tions in materials.
Solid-state NMR, SSNMR, is not as common as X-ray or DSC in phar-
maceutical cocrystal studies, though it can give detailed structural infor-
mation about cocrystals and complexes [73–76]. Typical production
methods for formulation of pharmaceutical cocrystals do not lead to sin-
gle crystal growth, which may complicate X-ray diffraction studies.
SSNMR are sensitive in recognizing molecular associations and struc-
tural features like hydrogen bonding. In SSNMR dipolar correlation ex-
periments between spin pairs like 1H\\1H, 1H\\13C, and 19F\\13C can
be utilized to determine hydrogen bonding, intermolecular contacts,
and spin diffusion, which link individual molecules together in a crystal
structure.
Reliable solid state characterization of material requires utilization
of more than one technique, andmostly thermal analyses are combined
with some spectroscopic techniques. In following section, case studies
demonstrating efficient combination of different techniques in analyz-
ing solid state of drug nanocrystals and nano-cocrystals are presented.
3.2.3. Solid state identification using combination of different techniques
Walsh et al. [77] made several different kinds of cocrystals with
sulfadimidine as a drug substance and 4-aminosalicylic acid as a hydro-
philic coformer. Solid state characterization of the systems by XRPD and
DSC is presented in the Fig. 6. DSC thermograms showed a single endo-
thermic peak characteristic for cocrystal melting point. Melting point of
cocrystals made by solvent evaporation technique was 175.84 °C, while
melting point for cocrystals produced by spray drying was 170.08 °C.
Besidesmelting point data, also other thermal information like enthalpy
of melting was reached from DSCmeasurements. Extremely fast drying
during spray drying induced crystal lattice imperfections, which
reflected on the thermal properties of the system. In all the systems
only endothermic melting point of cocrystals was seen. No exothermic
events were present. When cocrystal components were spray dried to-
gether with other excipients, XRPD analysis showed that cocrystalPlease cite this article as: L. Peltonen, Practical guidelines for the charac
cocrystals in the pharmaceut..., Adv. Drug Deliv. Rev. (2018), https://doi.oformation took place also in these systems; same characteristic diffrac-
tion peaks were seen in all these cocrystal samples.
In IR analysis interactions, like H-bonding, can be recognized
(Fig. 7) [77]. If carboxylic acid group is involved in hydrogen bonding
in cocrystals, IR is good technique to separate cocrystals from salts
[78]. In cocrystals neutral COOH-group shows a strong C_O
stretching peak at approximately 1700 cm−1 (in salts this peak is
not present) and a weak C\\O stretching peak approximately at
1200 cm−1. A carboxylate (-COO-) anion in salts has only a single
C\\O stretching peak in 1000–1400 cm−1. When sulfadimidine - 4-
aminosalicylic acid cocrystals were analyzed by attenuated total re-
flection Fourier transform IR, ATR-FTIR, at 3441 cm−1 asymmetric
and at 3339 cm−1 symmetric stretching bands of -NH2 group in 4-
aminosalicylic acid were detected [77]. Stretching band of NH
group of sulphonamide was seen at 3235 cm−1. Hydrogen bonding
in cocrystals was confirmed by one broad band at 3482 cm−1 and an-
other broad bandwith a N\\H stretching shoulder (NH2 amine group
in 4-aminosalicylic acid) at 3372 cm−1, which both were shifted to
lower values from 3493 cm−1 and 3386 cm−1, correspondingly. Be-
sides, sulfone stretching, -SO2, (in sulfadimidine) at 1315 cm−1,
and\\OH deformation in 4-aminosalicylic acid at 1275 cm−1 con-
firmed in this case the formation of cocrystals and that the formation
was based on hydrogen bonding.
Kumar and Burgess [79] studied naproxen nanocrystals made by
wet milling process. In modulated temperature DSC analysis they
found that increased amount of stabilizer (hydroxypropyl methyl cellu-
lose, HPMC) was seen in the thermogram as a lower melting tempera-
ture of naproxen indicating molecular level interactions between
naproxen and cellulose. Also in IR analysis peak shift were seen indicat-
ing formation of strong bond or molecular level interactions in the
system.
When spironolactone nanocrystalsweremadewith four different sta-
bilizers (poloxamers 188 and 407, HPMC and sodiumdeoxycholate),
spironolactone was in crystalline form II based on DSC analysis [80]. In
Raman analysis pure spironolactone showed four characteristic peaks in
the double bond region: C_O stretching of lactone ring (1766 cm−1),
thioacetyl group (1690 cm−1), C6 ring (1670 cm−1) and C_C stretching
(1616 cm−1), while the excipients did not have any peaks in that area.
Drug-excipient interaction studies were based on the characteristic drug
peaks: if characteristic peaks are not shifted, there are no interactions be-
tween the drug and excipient. Peaks at 1690–1670 cm−1 disappeared
with Poloxamer 407 stabilized spironolactone nanocrystals confirming
drug stabilizer interactions. With other excipients no peak shift/disap-
pearance and hence no interactions were noticed.
Changes in piroxicam crystal form during nanocrystallization by
high pressure homogenization were confirmed by XRD, FTIR and DSC
analysis [81]. The piroxicam raw material was in crystal form I and
white in color. After the nanocrystallization, nanosuspension was yel-
low in color and itwas found to be amixture of crystallinemonohydrate
and form III; monohydrate is yellow powder, whichwas already seen in
the colored appearance of the particles. In this case the solubility differ-
ence between the different crystalline forms of BCS class II drug
piroxicamwas evident: the solubility of form I is 14.3mg/L as compared
to solubility value of 17.0 mg/L for form III.
Carbamazepine is well-known example of a drug existing in many
different crystal forms. When carbamazepine nanocrystals were pro-
duced by electrospraying technique, XRD and DSC analysis showed
that drug was in amorphous form [69]. After fast water absorption
from the air, drug was transformed to anhydrated form. Eight hours
after production, XRD analysis showed large amorphous halo, but also
small peaks characteristic for form III were found. Further, after 12 h
characteristic peaks for form I were also seen, and during storage the
relative amounts of form I and form III changed again. Accordingly, the
storage stability of the system was poor, and transformation towards
more thermodynamically stable solid state form of the drug took place
fast during storage.terization and quality control of pure drug nanoparticles and nano-
rg/10.1016/j.addr.2018.06.009
Fig. 6. XRPD diffractograms and DSC thermograms of sulfadimidine cocrystals and co-spray dried systems. (i) XRPD of a) Cocrystals by spray drying, b) Cocrystals by slow solvent
evaporation, c) 4-aminosalicylic acid (coformer), d) sulfadimidine (drug). (ii) XRPD of co-spray dried systems with excipient: a) cocrystal by spray drying, b-e) cocrystal components
co-spray dried with b) dextran, c) inulin, d) MCC, e) mannitol. (iii) DSC thermograms of a) sulfadimidine, b) 4-aminosalicylic acid, c) cocrystals by spray drying, d) cocrystals by
solvent evaporation, e-h) cocrystal components co-spray dried with e) inulin, f) mannitol, g) MCC, h) dextran. Reprinted from [77] with permission from Elsevier.
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tems, and sometimes drug and excipient can form eutectic mixtures,
which can be detected by suitable analytical techniques. Formation of
eutectic mixture between ibuprofen and poloxamer in nanosuspension
was confirmed by DSC analysis [82]. The exothermic melting peak of
pure ibuprofen was at 74.8 °C, and for pure poloxamer at 51.4 °C. For
the nanosuspension, melting peak for eutectic mixture was seen at
39.4 °C and melting peak for the excess ibuprofen was seen at 56.8 °C.
Sander et al. [15] formulated caffeine and 2,4-dihydroxybenzoic acid
monohydrate nano-cocrystals by sonication process. In this case drug
and coformer made two-dimensional graphite like structure based on
intramolecular (OH (hydroxy group)\\O (carboxy group)) and inter-
molecular (OH (carboxy group)\\N (imidazole group)) hydrogen
bonding. Particle size and size deviation was determined by DLS, and
SEM confirmed the particle shape and morphology. CalculatedFig. 7. FTIR analyses of (a) co-spray dried sulfadimidine−4-aminosalicylic acid cocrystals
in inulin, (b) spray dried cocrystals, (c) inulin, (d) a physical mixture of sulfadimidine and
4-aminosalicylic acid. Reprinted from [77] with permission from Elsevier.
Please cite this article as: L. Peltonen, Practical guidelines for the charac
cocrystals in the pharmaceut..., Adv. Drug Deliv. Rev. (2018), https://doi.odiffractogram for the cocrystals gave peaks (2θ) at 10.78°, 12.98°,
17.48°, 21.58°, and 22.98°, and XRPD analysis confirmed successful for-
mation of cocrystals. SEM analysis showed formation of plate shaped
nanoparticles, and DLS measurements showed with the best formula-
tion average particle size to be 136 nm with polydispersity index
(PDI) value of 0.239, meaning formation of small and monodisperse
drug nano-cocrystals.
Spitzer et al. [65] made caffeine-oxalic acid (2:1 M ratio) and
caffeine-glutaric acid (1:1M ratio) nano-cocrystals by spray-flash evap-
oration process, where the crystallization rate is extremely fast. Particle
size, measured by atomic force microscope, AFM, was for caffeine-
glutaric acid cocrystals 111 nm and shape was acicular. Formation of
cocrystals was confirmed by XRD: diffractograms differed those of the
individual components and correspondedwell with the theoretical pat-
terns from Cambridge Structural Database and literature references.
From XRD results the coherent crystallite sizes were calculated from
the full width at half maximum (FWHM) of the X-ray signals. For both
the systems the formed nanoparticles contained five to ten single crys-
tals, because particle size values determined by AFM were approxi-
mately 2–3 times bigger than the corresponding coherent crystallite
size values. In the same study cocrystalline explosives, 2,4,6-trinitrotol-
uene - 1,3,5,7-tetranitro-1,3,5,7-tetraazacyclooctane (TNT-HMX), were
tried to formulate; in XRD analysis of the system the active agent
peaks were present but the coformer peaks were lacking. This system
was semi-crystalline in nature, not cocrystals: raw materials were
only physically mixed, not chemically combined viamolecular level in-
teractions, like is the case with cocrystals.
Further analyses were performed and DSC analysis confirmed the
above mentioned XRD results [65]. In TNT-HMX sample, which instead
of cocrystals formed physicalmixture, the TNTmelting peakwas seen in
DSC thermogram. In DSC, heating and cooling cycles were repeated.
When, after the first DSC heating, the system was cooled and heated
again, the TNT melting peak was similar to the peak in the first heating.
For another cocrystal system, carreine-oxalic acid nano-cocrystals, first
heating gave single melting peak for cocrystal, which was between theterization and quality control of pure drug nanoparticles and nano-
rg/10.1016/j.addr.2018.06.009
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oxalic acid was decomposed, when it was released from the cocrystal
structure. During the second heating, the melting peak of pure caffeine
was seen. Raman spectra further confirmed the DSC and XRD results,
when the Raman bands fitted to the published cocrystal vibrational
bands.
Vogt et al. [73] made SSNMR analysis for a number of well-known
pharmaceutical cocrystals, which were already characterized by XRD.
Formation of all the studied cocrystals was based mainly on hydrogen
bonding and 1H SSNMR was a powerful tool, because it was able to se-
lectively detect hydrogen bonds. For example, formation of binary
cocrystals of palmitic acid and nicotinamide was based on hydrogen
bondingbetween carboxylic acid donor of palmitic acid and pyridine ac-
ceptor in nicotinamide, whichwas detected by SSNMR. This structure is
common in cocrystals based on carboxylic acids and nitrogen bases.
SSNMR studies utilized a combination of 1D and 2D dipolar correlation
methods. Especially, in complex systems the SSNMR showed better sen-
sitivity as compared to XRD,where someof the peakswere overlapping.
In another study theophylline cocrystal structures were confirmed
by combining SSNMRand FTIR [74],whenhydrogenbond formation be-
tween theophylline and cocrystal former (carboxylic acid)was found in
SSNMR spectra. Two polymorphic forms of ethenzamide-gentisic acid
cocrystals were characterized by 13C and 15N SSNMR and FTIR [75]
and again changes in 13C and 15N chemical shift values for ethenzamide
molecule were observed, which confirmed intramolecular hydrogen
bonding in cocrystals. Formation mechanisms of caffeine-malonic acid
cocrystals were tracked in real time by 13C SSNMR [76].
In interpretation of nanoparticle analysis, it should be kept in mind
that with smallest nanosized particles melting temperature (for exam-
ple in DSC analyses) can be slightly shifted to lower temperatures, be-
cause the free energy of the system is higher and crystal energy lower
[48,80]. For example with valsartan, when the long-range order of crys-
tals was tens of nanometers, the lowering of melting temperature by
N20 °C was noticed as compared to normal sized valsartan crystals
[83]. In the samewaywith smallest particle size fractions peak broaden-
ing or lowered intensities can be seen in X-ray diffractograms [6,63].
This was demonstrated in a study by Aleandri et al. [63], where, based
on the DSC studies, fenofibrate and bezofibrate nanocrystals were in
crystalline form, but the diffraction intensities in X-ray diffractograms
were slightly decreased. The peak intensities were lowered due to the
decreased particle size in nanoscale and/or disorders in crystal struc-
ture, which were more pronounced in nanosized particles.
In solid state characterization, XRD is the golden standard. It has
been utilized for a long time and a lot of reference difractograms are
available in the literature. In combination with DSC, it gives enough
data for reliable solid state characterization, and that combination is rec-
ommend for solid state analysis. Benefits of DSC are small sample
amount, but the controlled heating during the analysis run may induce
changes in the sample. Raman is not as universal for all kind of themol-
ecules as XRD, and it also is less frequently used. If the laser power in
spectroscopic techniques is high or themeasurement time long, sample
can be burned, which can affect the results. In interaction studies IR is
powerful tool and first choice; if more precise information related to hy-
drogen bonding is needed, SSNMR is good option, though it cannot be
recommended as a standard analysis technique.
3.2.4. Chemical stability
All the above-described techniques can give some information also
about the chemical purity or degradation of the drug, butmost standard
way to detect this is high performance liquid chromatography, HPLC.
Impurities or degradation products are seen in HPLC as new peaks, but
recognition of side products often requires other techniques like liquid
chromatography - mass spectrometry, LC-MS. Degradation can be in-
duced by harsh process conditions, and exact knowledge of chemistry
of the unwanted products is crucial in order to recognize the problem-
atic process steps.Please cite this article as: L. Peltonen, Practical guidelines for the charac
cocrystals in the pharmaceut..., Adv. Drug Deliv. Rev. (2018), https://doi.oDegradation of naproxen during nanomilling was studied with two
stabilizers; hydroxypropyl methyl cellulose, HPMC, and Tween 80
[79]. Tween 80 stabilized nanocrystals were stable, but milling with
HPMC induced molecular level interactions between drug and stabi-
lizer, which were seen in MT-DSC analysis. Chemical degradation was
confirmed in HPLC analysis (Fig. 8), when extra degradation peaks
were present. In order to recognize the degradation product, LC-MS
analyses was run, and the degradation product peak was seen at 208
m/z. Peak intensity, i.e. degradation product concentration, was in-
creased with longer milling times. Based on literature and earlier stud-
ies, the most common degradation product of naproxen was identified
to be decarboxylated naproxen [84], and the LC-MS peak corresponded
sodium salt of decarboxylated naproxen.
Chemical stability and drug content analysis of itraconazole
nanocrystals prepared by sonoprecipitation technique were confirmed
by HPLC analysis [85]. After 3 months storage, the drug content had
not changed significantly, and no degradation peaks were noticed in
HPLC graph. When paclitaxel nanocrystals were produced by laser irra-
diation technique, particle sizewas approximately 400 nmwith narrow
particle size deviation [86]. However, the process was associated with
significant chemical degradation of paclitaxel due to high laser power.
The amount of paclitaxel and its degradation products in nanosuspension
after laser treatmentswas evaluated byHPLC technique and23.1% of pac-
litaxel was degraded.
Chemical stability of adefovir dipivoxil was improved by formation
of cocrystals with saccharin [87]. After 18 days of storage of the pure
drug, the total amount of impurities was 90.71%. Adefovir dipivoxil –
saccharin cocrystals had a significantly higher drug content and a signif-
icantly lower content of impurities at all the sampling points. After
47 days of storage, no significant content change was found in adefovir
dipivoxil–saccharin cocrystals; the total amount of impurities was b2%.
3.3. Drug release and solubility
For drug cocrystals, one should demonstrate that the pure drug is re-
leased from the cocrystal structure in vivo; for that, in vitro dissolution
and/or solubility testing has been considered to be sufficient [14].
Also, reliable dissolution method is crucial performance testing for
drug nanocrystals in order to confirm expected solubility and drug re-
lease profiles. Both drug nanocrystals aswell as nano-cocrystals are con-
siderably simple in structure, and their ability to improve the solubility
properties are well known in vitro. However, fast dissolution in vitro
does not necessarily lead to enhanced permeation in vivo, for example
due to drug precipitation before the adsorption, and this poses extra re-
quirement for finding a reliable and correlative drug release testing
platform for these systems. For drug nanosystems no compendial stan-
dards for drug release testing exist, and currently different methods
have been utilized, both including (modified) pharmacopoeial methods
as well as new techniques [88].
3.3.1. Apparent solubility and supersaturation
In the same way than with the other high energy state systems, like
amorphous systems or metastable polymorphic forms, with both the
drug nanocrystals and nano-cocrystals, the apparent solubility levels
reached in the dissolution testing are higher than the thermodynamic
solubility of the bulk drug. For example, apparent solubility in 0.5%
aqueous sodium dodecyl sulphate solution for fenofibrate nanocrystals
(size 460 nm) was 67.51 g/mL while the corresponding value for bulk
drug (particle size 80 μm)was only 6.02 g/mL [89]. Higher apparent sol-
ubility values can cause drug precipitation in more thermodynamically
stable form, i.e. less soluble form, after the initial fast dissolution [47,90].
This needs to be avoided/minimized by careful formulation planning in
order to reach the biopharmaceutical benefits with these systems
in vivo.
Further, this uncontrolled precipitation takes place on top of the
nanocrystals/nano-cocrystals, which even lowers the solubility ofterization and quality control of pure drug nanoparticles and nano-
rg/10.1016/j.addr.2018.06.009
Fig. 8. Degradation peaks of hydroxypropyl methylcellulose, HPMC, stabilized naproxen nanocrystals in HPLC. (Time is presented in x-axis and peak intensity in y-axis.) Reprinted from
[79] with permission from Elsevier.
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system equals to the solubility of the precipitated drug form. One strat-
egy to avoid uncontrolled precipitation of already dissolved nanocrystals
and nano-cocrystals is the use of crystallization inhibitors in the formu-
lation, i.e. polymers like HPMCor PVP [4,91–94]. In the case of cocrystals,
also excess amount of coformer can be used [95,96].
Higher apparent solubility and extremely fast dissolution rate with
these systems poses extra requirements for reliable in vitro dissolution
testing [11,97]. In small particle systems, particle size is highly related
to the dissolution rate and apparent solubility [28] and in order to
reach discriminating dissolution results, in vitro dissolution test can be
performedunder non-sink conditions. Another reason for non-sink con-
ditions in vitro is the evaluation of their ability to maintain supersatu-
rated state (solution stability), and the possibility to predict in vivo
performance of the systembyutilizing testing under these stressed con-
ditions. But, caremust be taken in order to interpret the results correctly
[11,97,98].
Generally, drug release data for supersaturated systems under non-
sink conditions are recognized as an evaluation method for their ability
to maintain supersaturated state (solution stability). Supersaturation
can also enhance the permeation; it was shown that the higher concen-
tration increased the membrane transport rate both with artificial and
biological membranes [99,100], reaching the maximum permeation
with the amorphous solubility value, where the liquid-liquid phase sep-
aration started [101,102].
Maintenance of supersaturation with different kinds of
supersaturating systems, namely carbamazepine nanocrystals and amor-
phous carbamazepine, was measured in real-time detection by 1H NMR
technique [103]. For carbamazepine nanocrystals (size 150 nm) dissolved
concentration was almost constant during 50 h time, while for amor-
phous carbamazine initial concentration was higher, but it was then
lowered below the stable concentration value with drug nanocrystals.
The lower level of supersaturation reached with drug nanocrystals was
more stable, while with amorphous drug the higher level of supersatura-
tion was kinetically less stable leading to precipitation. Shiraki et al. [104]
formulated exemestane-maleic acid and megestrol acetate-saccharin
cocrystals. While both improved intrinsic dissolution rate as compared
to the original bulk drug materials, exemestane cocrystals were trans-
formed to pure drug after 1min time in suspension, while transformation
for megestrol acetate cocrystals took 2–4 h in suspension, indicating
higher stability (Fig. 9). Solid state forms were confirmed by XRPD
technique.
Further challenges are faced in vivo, when for example pH changes in
gastro intestinal, GI, tract may alter the level of supersaturation drasti-
cally and induce uncontrolled precipitation [53]. For example, solubility
of itraconazole is approximately 250-times higher in stomach (acidic
pH) than in intestine (slightly basic pH). In vitro the dissolution ofPlease cite this article as: L. Peltonen, Practical guidelines for the charac
cocrystals in the pharmaceut..., Adv. Drug Deliv. Rev. (2018), https://doi.oitraconazole from drug nanocrystals was superior as compared to com-
mercial Sporanox® granules. However, when itraconazole nanocrystals
were packed in capsules and in vivo tests were performedwith rats, fast
dissolution of drug nanocrystals was followed by fast precipitation.
After dissolution drug in solution was immediately transited to intes-
tine, where the solubility of itraconazole was much lower, and fast pre-
cipitation took place. Fast precipitation inhibited absorption, and the area
under the curve, AUC, value with nanocrystals was lower as compared to
commercial Sporanox® granules. Hence, in vitro – in vivo correlation,
IVIVC could not be established. When itraconazole nanocrystals were at-
tached to cellulose matrix, enhanced bioavailability was realized [7]. Ac-
cordingly, with supersaturating systems in order to reach reliable IVIVC,
the importance of dissolution testing set-up cannot be overemphasized.
In order to evaluate the apparent solubility values and concentration
level differences between different nanoparticle size fractions, Sarnes
et al. [105] utilized UV imaging and channel flowmethods for solubility
studies of indomethacin nanocrystals. In both techniques, nanocrystals
were compressed into tablets and in theboth set-ups,flat tablet surfaces
wereflushedwithmedium. Accordingly, particle size effect on solubility
was neglected, and intrinsic dissolution values were measured. In UV-
imaging, concentration profiles on the compression surfaces showed
surface concentration value for drug nanocrystals (size 580 nm) being
28.7 mg/L, while the corresponding value for bulk drug surface was as
low as 2.1 mg/L. Drug concentration profiles as a function of distance
from the compact surface for different particle sizes and at different
time points are shown in Fig. 10. In channel flow equipment intrinsic
dissolution rates were clearly different even between different
nanosized particle fractions, too.
3.3.2. Dissolution testing
The official pharmacopoeia dissolution methods (European,
Japanese, United States Pharmacopoeia) are best for quality control pur-
poses and they are material and time consuming [106,107]. Often also
with fast dissolving samples, their sensitivity is not high enough. In-
stead, different imaging-based techniques, like UV, FTIR, near infrared
(NIR), magnetic resonance imaging (MRI), Raman and coherent anti-
Stokes Raman scattering (CARS) methods, which can give more precise
information about the dissolution process can be utilized or they can be
combined to traditional pharmacopoeia techniques [70,105,108–113].
Different kind of approach for dissolution studies was presented by
Kayaert et al. [114],when theymeasured dissolution rate of three differ-
ent drugs by solution calorimetry based on the temperature changes in
the reaction vessel. Temperature data were transformed to heat of
solution. All the drugs dissolved totally in b1 min time. Calorimetry
measures total heat production and consumption, and this can leadmis-
leading interpretations. For example, separating the heat ofmixing from
the heat of solution can be impossible.terization and quality control of pure drug nanoparticles and nano-
rg/10.1016/j.addr.2018.06.009
Fig. 9. XRPD diffractograms of (a) exemestane-maleic acid, and (b) megestrol acetate-saccharin cocrystals in suspension with different particle size fractions. XRPD confirms
transformation from cocrystals to pure drug. Reprinted by permission from Springer Nature from [104].
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dissolution testing, if the test conditions are tailored. Liu et al. [97]
modelled dissolution mechanisms for polydisperse nanoparticles in
order to find the best discriminating dissolution environment. Simula-
tions showed that when the sample amount equaled to the saturation
solubility of the measured sample, the discrimination power was best
between different nanosized fractions. When the concentration was
further increased, the discrimination power was lowered. Simulation
results were confirmed experimentally in pharmacopoeia basket
method. Accordingly, selection of dissolution medium and amount of
medium/sample are important factors.
Often the challenge in nanoparticle dissolution and solubility testing
is the separation of colloidal sized particles from the liquid phase before
the concentrationmeasurements.Mostly utilized techniques for separa-
tion are ultracentrifugation [48] andfiltration [115] or both together [8].
In filtering the smallest particles may pass through the filter or particles
can stack on the filter. Often in filtering only the pore size is taken into
account. But, also interactions between the drug and filter materialPlease cite this article as: L. Peltonen, Practical guidelines for the charac
cocrystals in the pharmaceut..., Adv. Drug Deliv. Rev. (2018), https://doi.oshould be taken care of. In centrifugation small nanoparticle require
high forces and long process times and dissolution may continue even
during the centrifugation or drug can be absorbed to the tube material.
When filtration with two different filter types and ultracentrifuga-
tion were compared as separation techniques for dissolution studies of
indomethacin nanocrystals, it was noticed that indomethacin was at-
tached to both the filter materials as well as to the centrifugation
tubes [97]. In that study, the filter still was the most reliable technique,
when the filter typewas carefully selected. If drug is interactingwith fil-
ter material, it is typical that during the filtering the first drops of the
sample has lower concentration, because the drug is attaching to the fil-
ter material. When the filter material is saturated with the drug, the
concentration of the filtrate is higher. In order to check the presence
of solid particles in the liquid sample, UV-spectrophotometric analysis
with two differentwavelengths can be beneficial [105]: onewavelength
at the drug absorption maximum for drug concentration determina-
tions and the other wavelengthwere the absorbance of drug and excip-
ients is negligible for confirmation of absence of undissolved particles.terization and quality control of pure drug nanoparticles and nano-
rg/10.1016/j.addr.2018.06.009
Fig. 10.Apparent drug concentration-distance from the compact surface -profiles by UV imaging for indomethacin nanoparticles with two different stabilizers (poloxamers F68 and F127)
at time points of 5, 15 and 30min. (A) F68/particle size 580±30nm, (B) F68/micronsized particles, (C) F127/particle size 580±20nm, (D) F127/micronsized particles and (E) bulk drug/
particle size tens of μm. Reprinted from [105] with permission from Elsevier.
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methods can be used in dissolution tests. For example, drug is put inside
of a dialysis bag, which is analyzed in pharmacopoeia basket or paddle
setups. However, if dialysis bags/membranes are used, care must be
taken in the membrane selection in order to avoid that the limited
membrane transport is in fact controlling the drug release [116,117].
This is often the problem with fast dissolving systems, like drug
nanocrystals and nano-cocrystals, or if there is a burst release in the be-
ginning of the dissolution process [118]. Drug can also interact with the
membrane material in the same way than with filters.
Drug release testing is important but demanding part of analysis for
nanosized drug systems, and no compendial or standard universal pro-
cedure exist for them [84,119]. Different techniques are available, phar-
macopoeia methods can be used, but often measurement conditions
need to be tailored case by case based on the aims of the testing (for ex-
ample, data for purely research purposes or quality control purposes).Please cite this article as: L. Peltonen, Practical guidelines for the charac
cocrystals in the pharmaceut..., Adv. Drug Deliv. Rev. (2018), https://doi.oSupersaturated drug delivery systems, like drug nanocrystals and
nano-cocrystals are extra demanding and may cause problems in
IVIVC. If the tests are performed under sink conditions in vitro, IVIVC
can be difficult to establish [53].
4. Conclusions
Physical stability (stable particle size and solid state form), solubility
behavior, and drug release testing are the most important functional
properties of drug nanocrystals and nano-cocrystals.
Particle size analysis can be performed by imaging or non-imaging
techniques. Non-imaging techniques are fast, reliable, and well suitable
for process control purposes. Sample heterogeneity may causemislead-
ing results, and it is advisable to confirm the particle size and shape in-
formation with some imaging technique, most preferable by electron
microscope technique.terization and quality control of pure drug nanoparticles and nano-
rg/10.1016/j.addr.2018.06.009
13L. Peltonen / Advanced Drug Delivery Reviews xxx (2018) xxx–xxxSolid state characterization can be done by spectroscopic or thermic
analysis. The more complicated the system is, for example the higher
number of excipients, more probable it is that part of the information
is overlapping each other. In order to reach reliable information of
solid state form, it is recommended to use more than one technique,
recommended combination is DSC as a thermal analysis and x-ray anal-
ysis. For drug nanocrystals, solid state confirmation is enough, but for
nano-cocrystals, requirement is confirmation of formation of cocrystal
structure. Standard method for interaction studies confirming the
cocrystal structure is IR techniques, but so far less utilized SSNMR is
also very good technique especially in recognizing hydrogen bonding.
In solubility and dissolution studies the aim of the studies should be
recognized. From these nanosystems dissolution is often so fast that
compendial methods do not have enough discriminative power for de-
tecting differences between the samples. Also supersaturating drug de-
livery systems, like drug nanocrystals and nano-cocrystals pose special
requirements for in vitro test methods if IVIVC correlation needs to be
found.
In the first screening studies with new chemical entity the sample
amount is very small. This states extra demands for the reliable analysis,
when only a limitednumber of tests can bedone. On theother hand, fast
and reliable information, for which the decision is based on, are highly
required. The importance of reliable and thorough in vitro characteriza-
tion of nanosystems can never be overemphasized. In order to reach
good IVIVC, mimicking of in vivo conditions is crucial. In nanosystems
even very small changes can have dramatic consequences in vivo bio-
availability, which may not be visible in vitro tests. Small scale sets
extra demands to the analytics and for example for drug release testing
no compendial or standard test protocol exist, which further increases
analytical challenge.
New techniques open up new possibilities, like for example new
spectroscopic techniques utilized in solid state analysis. These tech-
niques can givemore exact information for research purposes, but in in-
dustrial quality control purposes they are not the first choice. They
require much more research evidence to be suitable for every day pro-
cess control purposes. Traditional and well established techniques are
recommended for quality control purposes.
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